Stock Ratings / Health Care / QURE / forecast

KLRA (50) NBTX (52) STOK (59) CMPS (37) ⌘ Pro Terminal →

uniQure N.V. (QURE) 12-Month Stock Forecast & Price Target Cone

$25.30 +1.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.31

uniQure N.V. (QURE) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.75B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $25.31 (+0.05%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QURE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (52/100 Composite)

🔍 WHY QURE SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+14/20 pts (27% of score)

FRED Regime × Technicals: 39% of 52W Range • RSI-14 at 42.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$22.59-3.6% Next Q

Q2 (-2Q)

Grade D$21.78+3% Next Q

Q3 (-1Q)

Grade D$22.43+12.8% Next Q

Current

Grade D+$25.30-1.1% Hist 90D α

Trajectory: D (44) → D+ (52)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QURE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QURE currently carries a cautious 52/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($34.55) and Max Pain ($26.57) forces dealer call-delta covering toward $54.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QURE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “QURE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 52%NO 48%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your QURE Position Size: $10,000

Shares at $25.30: 395.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $19.20

$7,589

$-2,411 (-24.1%)

12M Consensus BaseTarget $24.62

$9,731

$-269 (-2.7%)

12M Bull Case BreakoutTarget $54.31

$21,466

+$11,466 (+114.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$26	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$51	69%	B
JP MorganUS Large-Cap Research	SELL	$22	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QURE)

✓Walkthrough of QURE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

QURE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +26.82%📐 HORIZONTAL RANGE

2026-10-30O $25.11H $25.30L $23.56C $25.30VOL 1.88M

RES: $53.12SUP: $19.88SMA50: $34.55SMA200: $29.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QURE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QURE Butterfly Map → + Track QURE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QURE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QURE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for QURE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QURE)

Health Care Rank #316 of 1016 ⚔️ KLRA vs QURE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QURE vs. KLRA, NBTX, STOK, CMPS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, uniQure N.V. (QURE) ranks #316 by composite RQD confidence (52/100, grade D+) and #281 by equity capitalization ($1.75B). Within this direct 5-issuer industry benchmark cohort, QURE leads on earnings valuation at N/A trailing P/E, while STOK leads on capital efficiency and profitability with -6.1% ROIC and — gross margin. STOK currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with QURE at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
QURE ACTIVE uniQure N.V.	D+	52/100	—	—	-35.0%	+1.32%	$1.75B	Benchmark Subject
KLRA Kailera Therapeutics Inc.	D	50/100	—	—	—	-0.07%	$1.74B	/klra-vs-qure →
NBTX Nanobiotix S.A.	D+	52/100	—	—	—	-0.53%	$1.72B	/nbtx-vs-qure →
STOK Stoke Therapeutics Inc.	C-	59/100	—	—	-6.1%	-0.23%	$1.70B	/stok-vs-qure →
CMPS COMPASS Pathways Plc American Depository Shares	D-	37/100	—	—	-35.0%	-0.73%	$1.69B	/cmps-vs-qure →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001590560

In its most recent audited fiscal period (FY2025, filed 2025-12-31), uniQure N.V. (QURE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$199.0M, operating cash flow of -$178.0M, and free cash flow of -$178.4M (+4.1% YoY). On the balance sheet, QURE closed FY2025 with $824.9M in total assets against $49.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$199.0M	-$178.0M	-$178.4M	$824.9M	$49.7M
FY2024 (FY)	2024-12-31	$0	-$239.6M	-$182.7M	-$186.1M	$556.5M	$51.3M
FY2023 (FY)	2023-12-31	$0	-$308.5M	-$145.9M	-$145.9M	—	—

3. QURE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QURE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, uniQure N.V. (NASDAQ: QURE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $25.30 (+1.32% 1D, market cap $1.75B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, QURE ranks #316 in composite RQD confidence.

How does QURE compare to KLRA and NBTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QURE carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KLRA (Kailera Therapeutics Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $1.74B) and NBTX (Nanobiotix S.A.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.72B). Among the 5-stock peer group, QURE leads on earnings multiple (N/A) while STOK leads on capital efficiency (-6.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QURE?

Per QURE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590560), uniQure N.V. generated $0 in revenue, -$199.0M in net income, and -$178.4M in free cash flow against $824.9M in total assets and $49.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QURE trading relative to its 50-day, 200-day, and 52-week technical levels?

QURE last traded at $25.30 (+1.32% on volume of 1,713,465 shares), positioning the stock -26.77% below its 50-day simple moving average ($34.55) and -14.67% below its 200-day simple moving average ($29.65). Across its 52-week range of $8.73 to $51.72, QURE sits at the 38.5% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($22.14 to $28.46).

QURE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is QURE's 12-month stock price target?

uniQure N.V. (QURE) carries a 12-month consensus base price target of $24.62 (-2.7% from $25.30), with a bull-case target of $54.31 and a bear-case floor of $19.2.